Batu Biologics Files Patent Covering New Use of Approved Drug for Decreasing Cancer Immunotherapy Toxicity
Company Aims to Provide Platform Allowing for Overcoming Rate Limiting Toxicity of Immunotherapy
Several years ago, the promise of immunotherapy was just a dream. Today, with the FDA approval of Provenge, the market entry of immunological checkpoint inhibitors, and the highly encouraging results of the CAR-T cell trials, immunotherapy of cancer is undergoing a renaissance.
Read the full article at businesswire.com